百诚医药：聘任陈卓雯为证券事务代表

Group 1 - The company Baicheng Pharmaceutical announced the resignation of Ms. Xu Yi as the representative of securities affairs due to personal reasons [1] - The company appointed Ms. Chen Zhuowen as the new representative of securities affairs, effective from the date of the board meeting on August 26, 2025, until the end of the current board term [1] - For the year 2024, Baicheng Pharmaceutical's revenue composition is as follows: 90.22% from CRO business, 5.2% from CDMO business, and 4.58% from commercial production [1] Group 2 - As of the report, Baicheng Pharmaceutical has a market capitalization of 6.1 billion yuan [2]